Review



codon optimized s pyogenes cas9 protein  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Addgene inc codon optimized s pyogenes cas9 protein
    (A) Schematic workflow of the pooled <t>CRISPR/Cas9</t> gene knockout screen. Cas9-expressing chromaffin cells were generated via lentiviral transduction and blasticidin selection. Cells were then transduced with a genome-wide sgRNA library, selected with puromycin, and cultured for 10 population doublings before genomic DNA extraction. sgRNA abundance was quantified at initial and final times by deep sequencing, and data were analyzed using the MAGeCK pipeline. (B) Ranked Robust Rank Aggregation (RRA) scores of the most significantly depleted genes from the screen. (C) Ranked RRA scores of the most significantly enriched genes from the screen. (D) Volcano plot of CRISPR screen results showing significantly depleted genes (blue) versus non-significant genes (gray). The x-axis represents log₂(fold change) (Log₂FC) in sgRNA abundance, and the y-axis shows –log₁₀ P values from MAGeCK analysis. (E) Volcano plot showing significantly enriched genes (red) versus non-significant genes (gray).
    Codon Optimized S Pyogenes Cas9 Protein, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 368 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/codon optimized s pyogenes cas9 protein/product/Addgene inc
    Average 96 stars, based on 368 article reviews
    codon optimized s pyogenes cas9 protein - by Bioz Stars, 2026-05
    96/100 stars

    Images

    1) Product Images from "Unbiased CRISPR Synthetic Lethal Screening for Genetic Vulnerabilities in Succinate Dehydrogenase (SDH)-loss Model of Paraganglioma"

    Article Title: Unbiased CRISPR Synthetic Lethal Screening for Genetic Vulnerabilities in Succinate Dehydrogenase (SDH)-loss Model of Paraganglioma

    Journal: bioRxiv

    doi: 10.1101/2025.08.26.672429

    (A) Schematic workflow of the pooled CRISPR/Cas9 gene knockout screen. Cas9-expressing chromaffin cells were generated via lentiviral transduction and blasticidin selection. Cells were then transduced with a genome-wide sgRNA library, selected with puromycin, and cultured for 10 population doublings before genomic DNA extraction. sgRNA abundance was quantified at initial and final times by deep sequencing, and data were analyzed using the MAGeCK pipeline. (B) Ranked Robust Rank Aggregation (RRA) scores of the most significantly depleted genes from the screen. (C) Ranked RRA scores of the most significantly enriched genes from the screen. (D) Volcano plot of CRISPR screen results showing significantly depleted genes (blue) versus non-significant genes (gray). The x-axis represents log₂(fold change) (Log₂FC) in sgRNA abundance, and the y-axis shows –log₁₀ P values from MAGeCK analysis. (E) Volcano plot showing significantly enriched genes (red) versus non-significant genes (gray).
    Figure Legend Snippet: (A) Schematic workflow of the pooled CRISPR/Cas9 gene knockout screen. Cas9-expressing chromaffin cells were generated via lentiviral transduction and blasticidin selection. Cells were then transduced with a genome-wide sgRNA library, selected with puromycin, and cultured for 10 population doublings before genomic DNA extraction. sgRNA abundance was quantified at initial and final times by deep sequencing, and data were analyzed using the MAGeCK pipeline. (B) Ranked Robust Rank Aggregation (RRA) scores of the most significantly depleted genes from the screen. (C) Ranked RRA scores of the most significantly enriched genes from the screen. (D) Volcano plot of CRISPR screen results showing significantly depleted genes (blue) versus non-significant genes (gray). The x-axis represents log₂(fold change) (Log₂FC) in sgRNA abundance, and the y-axis shows –log₁₀ P values from MAGeCK analysis. (E) Volcano plot showing significantly enriched genes (red) versus non-significant genes (gray).

    Techniques Used: CRISPR, Gene Knockout, Expressing, Generated, Transduction, Selection, Genome Wide, Cell Culture, DNA Extraction, Sequencing



    Similar Products

    codon optimized s pyogenes cas9 protein  (Addgene inc)
    96
    Addgene inc codon optimized s pyogenes cas9 protein
    (A) Schematic workflow of the pooled <t>CRISPR/Cas9</t> gene knockout screen. Cas9-expressing chromaffin cells were generated via lentiviral transduction and blasticidin selection. Cells were then transduced with a genome-wide sgRNA library, selected with puromycin, and cultured for 10 population doublings before genomic DNA extraction. sgRNA abundance was quantified at initial and final times by deep sequencing, and data were analyzed using the MAGeCK pipeline. (B) Ranked Robust Rank Aggregation (RRA) scores of the most significantly depleted genes from the screen. (C) Ranked RRA scores of the most significantly enriched genes from the screen. (D) Volcano plot of CRISPR screen results showing significantly depleted genes (blue) versus non-significant genes (gray). The x-axis represents log₂(fold change) (Log₂FC) in sgRNA abundance, and the y-axis shows –log₁₀ P values from MAGeCK analysis. (E) Volcano plot showing significantly enriched genes (red) versus non-significant genes (gray).
    Codon Optimized S Pyogenes Cas9 Protein, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/codon optimized s pyogenes cas9 protein/product/Addgene inc
    Average 96 stars, based on 1 article reviews
    codon optimized s pyogenes cas9 protein - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    human-codon optimized mrna sequence s. pyogens cas9 protein  (Intellia Therapeutics)
    90
    Intellia Therapeutics human-codon optimized mrna sequence s. pyogens cas9 protein
    Summary of ongoing or completed clinical trials utilizing LNPs. Formulation information is provided anywhere possible. Additional sources used in the construction of this table: https://clinicaltrials.gov ; https://classic.clinicaltrials.gov ; https://www.cdek.liu.edu . N/A: Formulation information not found, or any information identified were not peer-reviewed and not included.
    Human Codon Optimized Mrna Sequence S. Pyogens Cas9 Protein, supplied by Intellia Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human-codon optimized mrna sequence s. pyogens cas9 protein/product/Intellia Therapeutics
    Average 90 stars, based on 1 article reviews
    human-codon optimized mrna sequence s. pyogens cas9 protein - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Schematic workflow of the pooled CRISPR/Cas9 gene knockout screen. Cas9-expressing chromaffin cells were generated via lentiviral transduction and blasticidin selection. Cells were then transduced with a genome-wide sgRNA library, selected with puromycin, and cultured for 10 population doublings before genomic DNA extraction. sgRNA abundance was quantified at initial and final times by deep sequencing, and data were analyzed using the MAGeCK pipeline. (B) Ranked Robust Rank Aggregation (RRA) scores of the most significantly depleted genes from the screen. (C) Ranked RRA scores of the most significantly enriched genes from the screen. (D) Volcano plot of CRISPR screen results showing significantly depleted genes (blue) versus non-significant genes (gray). The x-axis represents log₂(fold change) (Log₂FC) in sgRNA abundance, and the y-axis shows –log₁₀ P values from MAGeCK analysis. (E) Volcano plot showing significantly enriched genes (red) versus non-significant genes (gray).

    Journal: bioRxiv

    Article Title: Unbiased CRISPR Synthetic Lethal Screening for Genetic Vulnerabilities in Succinate Dehydrogenase (SDH)-loss Model of Paraganglioma

    doi: 10.1101/2025.08.26.672429

    Figure Lengend Snippet: (A) Schematic workflow of the pooled CRISPR/Cas9 gene knockout screen. Cas9-expressing chromaffin cells were generated via lentiviral transduction and blasticidin selection. Cells were then transduced with a genome-wide sgRNA library, selected with puromycin, and cultured for 10 population doublings before genomic DNA extraction. sgRNA abundance was quantified at initial and final times by deep sequencing, and data were analyzed using the MAGeCK pipeline. (B) Ranked Robust Rank Aggregation (RRA) scores of the most significantly depleted genes from the screen. (C) Ranked RRA scores of the most significantly enriched genes from the screen. (D) Volcano plot of CRISPR screen results showing significantly depleted genes (blue) versus non-significant genes (gray). The x-axis represents log₂(fold change) (Log₂FC) in sgRNA abundance, and the y-axis shows –log₁₀ P values from MAGeCK analysis. (E) Volcano plot showing significantly enriched genes (red) versus non-significant genes (gray).

    Article Snippet: Parental imCC lines were made to express Cas9 by transduction with 3 rd generation lentiviral particles carrying codon-optimized S. pyogenes Cas9 protein and blasticidin resistance driven from the EFS promoter (Addgene # 52962-LV).

    Techniques: CRISPR, Gene Knockout, Expressing, Generated, Transduction, Selection, Genome Wide, Cell Culture, DNA Extraction, Sequencing

    Summary of ongoing or completed clinical trials utilizing LNPs. Formulation information is provided anywhere possible. Additional sources used in the construction of this table: https://clinicaltrials.gov ; https://classic.clinicaltrials.gov ; https://www.cdek.liu.edu . N/A: Formulation information not found, or any information identified were not peer-reviewed and not included.

    Journal: International Journal of Pharmaceutics: X

    Article Title: Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery

    doi: 10.1016/j.ijpx.2024.100283

    Figure Lengend Snippet: Summary of ongoing or completed clinical trials utilizing LNPs. Formulation information is provided anywhere possible. Additional sources used in the construction of this table: https://clinicaltrials.gov ; https://classic.clinicaltrials.gov ; https://www.cdek.liu.edu . N/A: Formulation information not found, or any information identified were not peer-reviewed and not included.

    Article Snippet: NTLA-2001 , NCT04601051 NCT06128629 , Phase 1 (2020–2026) Phase 3 (2023–2028) , LNP-encapsulated single guide RNA (sgRNA) targeting human TTR and a human-codon optimized mRNA sequence of S. pyogens Cas9 protein , N/A , Transthyretin (ATTR) amyloidosis with cardiomyopathy , IV , ( ) , Intellia Therapeutics , Active, not recruiting Recruiting.

    Techniques: Formulation, Virus, Membrane, Binding Assay, Recombinant, Vaccines, Modification, Infection, Expressing, Small Interfering RNA, CRISPR, Sequencing